Published in Infect Immun on July 01, 1996
Pathogenesis of group A streptococcal infections. Clin Microbiol Rev (2000) 15.35
Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev (1999) 7.76
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
Streptococcus adherence and colonization. Microbiol Mol Biol Rev (2009) 2.83
Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev (2005) 2.36
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Mutually exclusive distribution of IS1548 and GBSi1, an active group II intron identified in human isolates of group B streptococci. J Bacteriol (2001) 1.84
Mosaicism in the alpha-like protein genes of group B streptococci. Proc Natl Acad Sci U S A (2000) 1.83
Identification of novel adhesins from Group B streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding. Infect Immun (2002) 1.77
The SrtA Sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine. Infect Immun (2005) 1.75
Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun (1997) 1.60
The group B streptococcal C5a peptidase is both a specific protease and an invasin. Infect Immun (2002) 1.52
Improved pattern for genome-based screening identifies novel cell wall-attached proteins in gram-positive bacteria. Infect Immun (2001) 1.47
A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen. J Clin Invest (2003) 1.36
Emergence and global dissemination of host-specific Streptococcus agalactiae clones. MBio (2010) 1.35
Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun (2001) 1.29
Streptococcus thermophilus cell wall-anchored proteinase: release, purification, and biochemical and genetic characterization. Appl Environ Microbiol (2000) 1.22
Genetic polymorphisms of group B streptococcus scpB alter functional activity of a cell-associated peptidase that inactivates C5a. Infect Immun (2000) 1.18
Abundance of the delta subunit of RNA polymerase is linked to the virulence of Streptococcus agalactiae. J Bacteriol (2006) 1.04
Molecular epidemiology and genomics of group A Streptococcus. Infect Genet Evol (2014) 1.00
Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes. Infect Immun (2003) 0.99
Interspecies communication among commensal and pathogenic streptococci. MBio (2013) 0.94
Protease-dependent mechanisms of complement evasion by bacterial pathogens. Biol Chem (2012) 0.94
Characterization of the streptococcal C5a peptidase using a C5a-green fluorescent protein fusion protein substrate. J Bacteriol (2000) 0.91
Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice. Infect Immun (2002) 0.90
High-affinity interaction between fibronectin and the group B streptococcal C5a peptidase is unaffected by a naturally occurring four-amino-acid deletion that eliminates peptidase activity. Infect Immun (2006) 0.90
Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun (2005) 0.88
Human serum induces streptococcal c5a peptidase expression. Infect Immun (2009) 0.83
Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes. J Bacteriol (2002) 0.81
Whole-Genome Comparison Uncovers Genomic Mutations between Group B Streptococci Sampled from Infected Newborns and Their Mothers. J Bacteriol (2015) 0.81
Putative novel surface-exposed Streptococcus agalactiae protein frequently expressed by the group B streptococcus from Zimbabwe. Clin Vaccine Immunol (2009) 0.80
Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model. Am J Obstet Gynecol (2011) 0.79
Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase. PLoS Pathog (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Progressive sequence alignment as a prerequisite to correct phylogenetic trees. J Mol Evol (1987) 41.41
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (1986) 15.84
Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science (1995) 4.27
Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases. Protein Eng (1991) 2.95
C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun (1996) 2.77
The group A streptococcal virR49 gene controls expression of four structural vir regulon genes. Infect Immun (1995) 2.33
Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes. J Biol Chem (1990) 2.31
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants. J Infect Dis (1987) 1.88
Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol (1988) 1.83
Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun (1992) 1.68
Surface protein-CAT reporter fusions demonstrate differential gene expression in the vir regulon of Streptococcus pyogenes. Mol Microbiol (1992) 1.59
Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci. Infect Immun (1991) 1.47
Translational attenuation control of ermSF, an inducible resistance determinant encoding rRNA N-methyltransferase from Streptomyces fradiae. J Bacteriol (1988) 1.45
Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus. Biochem J (1991) 1.31
Similarity between the group B and A streptococcal C5a peptidase genes. Infect Immun (1992) 1.27
Purification of the proteinase from group B streptococci that inactivates human C5a. Biochim Biophys Acta (1991) 1.17
Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species. Infect Immun (1993) 1.15
The effect of type-specific polysaccharide capsule on the clearance of group B streptococci from the lungs of infant and adult rats. J Infect Dis (1992) 1.13
Differential expression of genes in the vir regulon of Streptococcus pyogenes is controlled by transcription termination. Mol Gen Genet (1996) 0.90
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA (1997) 5.24
Diagnosis and management of infective endocarditis and its complications. Circulation (1999) 4.77
Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis (1998) 3.18
C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun (1996) 2.77
Group B streptococcal Ibc protein antigen: distribution of two determinants in wild-type strains of common serotypes. J Clin Microbiol (1984) 2.55
Streptococcus pyogenes type 12 M protein gene regulation by upstream sequences. J Bacteriol (1987) 2.54
Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis (1999) 2.50
Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad Sci U S A (1994) 2.39
Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A (1985) 2.38
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation (1997) 2.32
Diagnosis and therapy of Kawasaki disease in children. Circulation (1993) 2.32
Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes. J Biol Chem (1990) 2.31
Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J Immunol (1982) 2.27
Physical characterization of ten R plasmids obtained from an outbreak of nosocomial Klebsiella pneumoniae infections. Antimicrob Agents Chemother (1979) 2.21
Coregulation of type 12 M protein and streptococcal C5a peptidase genes in group A streptococci: evidence for a virulence regulon controlled by the virR locus. J Bacteriol (1990) 2.16
Insertional inactivation of streptolysin S expression in Streptococcus pyogenes. J Bacteriol (1983) 2.13
Nosocomial multiply resistant Klebsiella pneumoniae: epidemiology of an outbreak of apparent index case origin. Antimicrob Agents Chemother (1979) 2.13
Epidemiology of group-B streptococcal carriage in pregnant women and newborn infants. J Med Microbiol (1977) 2.12
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
Capsular K1 polysaccharide of Escherichia coli: relationship to virulence in newborn rats and resistance to phagocytosis. Infect Immun (1979) 2.08
Identification of a divergent M protein gene and an M protein-related gene family in Streptococcus pyogenes serotype 49. J Bacteriol (1989) 2.04
Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J Infect Dis (1998) 2.01
DNA fingerprinting of Streptococcus zooepidemicus (Lancefield group C) as an aid to epidemiological study. J Infect Dis (1987) 1.99
Inhibition of alternative complement pathway opsonization by group A streptococcal M protein. J Infect Dis (1979) 1.97
Fc-receptor and M-protein genes of group A streptococci are products of gene duplication. Proc Natl Acad Sci U S A (1989) 1.97
In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants. J Infect Dis (1987) 1.88
Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol (1988) 1.83
Dynamics of Escherichia coli infection and meningitis in infant rats. Infect Immun (1978) 1.82
Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis (2000) 1.79
Group A streptococcal serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. J Infect Dis (1989) 1.75
Streptococcus pyogenes serotype M1 encodes multiple pathways for entry into human epithelial cells. Infect Immun (1998) 1.70
Human neutrophil chemotactic response to group A streptococci: bacteria-mediated interference with complement-derived chemotactic factors. Infect Immun (1983) 1.70
Maternal factors that enhance the acquisition of group-B streptococci by newborn infants. J Med Microbiol (1980) 1.70
Nucleotide substitutions and small-scale insertion produce size and antigenic variation in group A streptococcal M1 protein. Mol Microbiol (1993) 1.66
Expression of M type 12 protein by a group A streptococcus exhibits phaselike variation: evidence for coregulation of colony opacity determinants and M protein. Infect Immun (1987) 1.66
Comparison of epidemic and endemic group G streptococci by restriction enzyme analysis. J Clin Microbiol (1990) 1.60
Coagulase-negative staphylococcal septicemia: experience in a newborn intensive care unit. J Pediatr (1982) 1.60
Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun (1997) 1.60
Deletion and complementation analysis of biotin gene cluster of Escherichia coli. J Bacteriol (1972) 1.57
Characterization of prototype and clinically defined strains of Streptococcus suis by genomic fingerprinting. J Clin Microbiol (1990) 1.56
Location of promoter and operator sites in the biotin gene cluster of Escherichia coli. Proc Natl Acad Sci U S A (1972) 1.55
Influence of growth temperature of Escherichia coli on K1 capsular antigen production and resistance to opsonization. Infect Immun (1983) 1.54
Molecular species of R-protein antigens produced by clinical isolates of group B streptococci. J Clin Microbiol (1989) 1.54
Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis (1995) 1.53
Production of bacteremia and meningitis in infant rats with group B streptococcal serotypes. Infect Immun (1980) 1.52
Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams). Pediatrics (1984) 1.51
Evidence for group A-related M protein genes in human but not animal-associated group G streptococcal pathogens. Microb Pathog (1987) 1.51
High-frequency intracellular invasion of epithelial cells by serotype M1 group A streptococci: M1 protein-mediated invasion and cytoskeletal rearrangements. Mol Microbiol (1999) 1.48
Genetic instability of M protein and serum opacity factor of group A streptocci: evidence suggesting extrachromosomal control. Infect Immun (1975) 1.44
Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest (1972) 1.40
The relation of the Ibc protein antigen to the opsonization differences between strains of type II group B streptococci. J Infect Dis (1985) 1.39
VirR and Mry are homologous trans-acting regulators of M protein and C5a peptidase expression in group A streptococci. Mol Gen Genet (1993) 1.39
Effect of differences in antibody and complement requirements on phagocytic uptake and intracellular killing of "c" protein-positive and -negative strains of type II group B streptococci. Infect Immun (1987) 1.39
Pharyngeal carriage of group B streptococci: detection by three methods. J Clin Microbiol (1977) 1.38
Molecular analysis of multiple isolates of the major serotypes of group B streptococci. J Clin Microbiol (1993) 1.38
Localization and characterization of the hippuricase activity of group B streptococci. Infect Immun (1973) 1.37
Resistance to phagocytosis by group A streptococci: failure of deposited complement opsonins to interact with cellular receptors. J Immunol (1985) 1.37
Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet Gynecol (2000) 1.36
Identification of epidemic strains of Streptococcus suis by genomic fingerprinting. J Clin Microbiol (1991) 1.36
A DNA substitution in the group A streptococcal bacteriophage SP24. Virology (1983) 1.34
Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J Lab Clin Med (1996) 1.34
Evidence consistent with horizontal transfer of the gene (emm12) encoding serotype M12 protein between group A and group G pathogenic streptococci. Infect Immun (1992) 1.32
Congenital candidiasis. Am J Dis Child (1981) 1.32
Rapid pulsed-field gel electrophoresis method for group B streptococcus isolates. J Clin Microbiol (2001) 1.29
Invasive Scopulariopsis in the immunocompromised host. Am J Med (1987) 1.27
Similarity between the group B and A streptococcal C5a peptidase genes. Infect Immun (1992) 1.27
Bacteriophage control of antiphagocytic determinants in group A streptococci. J Exp Med (1980) 1.25
Cloning and expression of the gene for an immunoglobulin G Fc receptor protein from a group A streptococcus. Infect Immun (1987) 1.25
Plasmid macroevolution in a nosocomial environment: demonstration of a persistent molecular polymorphism and construction of a cladistic phylogeny on the basis of restriction data. Mol Gen Genet (1984) 1.24
Architecture of the vir regulons of group A streptococci parallels opacity factor phenotype and M protein class. J Bacteriol (1992) 1.22
Purification and characteristics of the streptococcal chemotactic factor inactivator. Infect Immun (1985) 1.22
Insertional inactivation of virR in Streptococcus pyogenes M49 demonstrates that VirR functions as a positive regulator of ScpA, FcRA, OF, and M protein. FEMS Microbiol Lett (1995) 1.18
Adherence of Haemophilus influenzae to human epithelial cells. Scand J Infect Dis (1984) 1.17
Purification of the proteinase from group B streptococci that inactivates human C5a. Biochim Biophys Acta (1991) 1.17
Agrobacterium infections in humans: experience at one hospital and review. Clin Infect Dis (1993) 1.16
Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis (1998) 1.16
Localization of the streptococcal C5a peptidase to the surface of group A streptococci. Infect Immun (1986) 1.15
Cloning and expression of the streptococcal C5a peptidase gene in Escherichia coli: linkage to the type 12 M protein gene. Infect Immun (1989) 1.15
Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein. J Immunol (1987) 1.13
Hospital distribution, persistence, and reintroduction of related gentamicin R plasmids. Antimicrob Agents Chemother (1986) 1.13
Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J (1991) 1.11
Type M12 protein from Streptococcus pyogenes is a receptor for IgG3. J Immunol (1993) 1.11
Neonatal malaria due to Plasmodium vivax. J Pediatr (1974) 1.10
Possible dual function of M protein: resistance to bacteriophage A25 and resistance to phagocytosis by human leukocytes. Infect Immun (1977) 1.08
Genetic dissection of the Streptococcus pyogenes M1 protein: regions involved in fibronectin binding and intracellular invasion. Microb Pathog (2001) 1.07
Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates. J Clin Microbiol (1999) 1.07
Susceptibility of phenotypic variants of Haemophilus influenzae type b to serum bactericidal activity: relation to surface lipopolysaccharide. J Infect Dis (1986) 1.06
Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin Infect Dis (1997) 1.06
Biochemical and immunological characterization of the extracellular nucleases of group B streptococci. J Exp Med (1980) 1.06
Antibody response to bacteriophage hyaluronidase in acute glomerulonephritis after group A streptococcal infection. J Infect Dis (1987) 1.05
Comparison of the antibody response to streptococcal cellular and extracellular antigens in acute pharyngitis. J Pediatr (1974) 1.04
A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5beta 1-fibronectin-M1 protein complexes. Proc Natl Acad Sci U S A (2000) 1.02
M12 protein from Streptococcus pyogenes is a receptor for immunoglobulin G3 and human albumin. Infect Immun (1994) 1.02
Identification of two type IIa IgG-binding proteins expressed by a single group A streptococcus. J Immunol (1992) 1.02
Hyaluronic acid capsule: strategy for oxygen resistance in group A streptococci. J Bacteriol (1979) 1.02
Analysis of restriction fragment length polymorphisms of the insertion sequence IS1381 in group B Streptococci. J Infect Dis (2000) 1.01